European Commission Approves KEYTRUDA Plus LENVIMA for Patients With Endometrial Carcinoma
Merck and Eisai announced that the European Commission has approved the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for the treatment of advance...
December 2, 2021
by AmericanPharmaceuticalReview
Imfinzi Approved in China for Small Cell Lung Cancer
AstraZeneca’s Imfinzi (durvalumab) has been approved in China for the 1st-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with standard of care platinum chemotherapy (etoposide plus a choice of ...
July 20, 2021
by americanpharmaceuticalreview
A Glimpse of the Oncology Drug Treatment Market in China
According to statistics, the market size of China’s oncology treatment industry reached RMB387.6 billion in 2020, with a compound annual growth rate of 10.3% in the past five years as compared to RMB261.4 billion in 2016, and this market size is expected
May 31, 2021
by PharmaSources/Xiaoyaowan
Using personalized medicine to avoid resistance to leukemia treatment
T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20.
May 11, 2021
by worldpharmanews
Chemotherapy uptake to gradually decrease with arrival of novel therapies and biosimilars- GlobalData
Trends in chemotherapy sales are expected to vary widely with CAGRs ranging from -14.92 per cent to 8.40 per cent across 15 major.
March 26, 2021
by expresspharma
FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy
The U.S. Food and Drug Administration (FDA) approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage ...
February 22, 2021
by americanpharmaceuticalreview
ICR urges change as NICE rejects Keytruda plus chemotherapy
The Institute for Cancer Research (ICR) has called for change in the way immunotherapy drugs are researched and evaluated after the National Institute for Health and Care Excellence (NICE) handed MSD’s Keytruda plus chemotherapy a rejection.
October 26, 2020
by pharmatimes
Avelumab significantly improves advanced bladder cancer patient survival
A Phase III trial concluded that avelumab is an effective maintenance therapy for patients with advanced or metastatic urothelial carcinoma, whose disease had not progressed after chemotherapy.
September 22, 2020
by europeanpharmaceuticalreview
Post-surgery chemo halves risk of recurring rare kidney cancer
A new trial has revealed that chemotherapy after surgery can reduce the risk of cancer of the ureter and renal pelvis returning by half.
March 9, 2020
by pharmatimes
Microcapsules provide targeted chemotherapy drug delivery to cancer cells
Development of infrared light-sensitive microcapsules could be the future in targeted drug delivery for cancer treatment, says new research.
December 12, 2019
by europeanpharmaceuticalreview
Full Chemo Doses May Improve Survival in Breast Cancer
Maintaining full doses of chemotherapy, especially early in the treatment course, is important for survival of intermediate or high-risk breast cancer patients...
September 12, 2019
by drugs
Chemotherapy is Out-of-date? Global Chemotherapy Demands will be Doubled in 2040, with China Having the Highest Demands!
Many people consider that the status of chemotherapy in cancer treatment has fallen considerably and some even consider chemotherapy to be out-of-date in recent years with the occurrence of targeted drugs and immunotherapy. Is chemotherapy useless?
September 4, 2019
by PharmaSources/Yefenghong